로딩 중...
52주 최고가 대비 82.2% 위치
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
SEC 13F 공시 기준 · 2025-Q4
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $901.0M | $1.09B | $1.19B | $1.24B |
| 영업이익 | - | $215.0M | $247.0M | $234.0M | $265.0M |
| 당기순이익 | - | $-44.0M | $-126.0M | $7.0M | $210.0M |
| 잉여현금흐름 (FCF) | - | $-9.0M | $-353.0M | $5.0M | $-94.0M |
| 수익성 비율 | |||||
| 영업이익률 | - | 23.9% | 22.6% | 19.7% | 21.4% |
| 순이익률 | - | -4.9% | -11.5% | 0.6% | 16.9% |
| ROE (자기자본이익률) | - | -86.3% | 65.6% | -2.1% | -212.1% |
| ROA (자산이익률) | - | -2.5% | -7.2% | 0.5% | 17.5% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 21.3% | 8.7% | 4.3% |
| EPS 성장률 (YoY) | - | - | 102.6% | -3700.0% | 555.6% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | 1764.0x | - | 21.6x |
| PBR (주가순자산배수) | - | 56.3x | - | - | - |
| PSR (주가매출배수) | - | 3.2x | 1.9x | 1.2x | 3.4x |
| FCF Yield | - | -0.3% | -16.9% | 0.4% | -2.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 5.43 | -1.47 | -1.11 | -3.55 |
| 유동비율 | - | 1.24 | 0.98 | 0.90 | 0.71 |
MOLINA HEALTHCARE INC
$179.86
$9.4B